At #KidneyWeek2025, CEO Dr. Xuehai Liang, Ph.D. shared exciting data showing ART5 boosted PC1 protein by ~50% and reversed cysts in preclinical models.

Arnatar’s ACT-UP1 platform is driving a new era in #RNAtherapeutics.

Explore more: arnatar.com/pipeline

Alagille syndrome (ALGS) is caused by 𝘑𝘈𝘎1 haploinsufficiency, leading to reduced Jagged1 protein and impairment of bile ducts.

Arnatar’s ART4, an upregulating ASO for 𝘑𝘈𝘎1, restores Jagged1 and liver function in ALGS models—now advancing in humans.

Learn more: arnatar.com/pipeline

New preclinical data from Arnatar’s ACT-UP1 platform will be presented at @asnkidney.bsky.social’s #KidneyWeek25 (Nov 5–9, Houston) & @aasldnews.bsky.social’s #LiverMeeting25 (Nov 7–11, DC). Exploring novel RNA therapies for #ADPKD, #LiverFibrosis & #ALGS.

🧬 www.arnatar.com/news/arnatar...

New paper from Arnatar CEO Dr. Xuehai Liang in Molecular Therapy–Nucleic Acids: ASO-mediated upregulation of #JAG1 improves bile duct development & liver markers in #ALGS mouse models—hinting at a disease-modifying path.

🧬 Read the full article: https://bit.ly/4h4VSej #ASO

We’re proud to introduce our Co-founder & CEO, Xuehai Liang, PhD, a pioneer in #RNA and #AntisenseTherapeutics. With 25+ years in #DrugDiscovery, 100+ publications & 30+ patents, he’s driving Arnatar’s mission to deliver next-gen RNA medicines.

🧬 https://www.arnatar.com/our-team

Arnatar was founded by Drs. Xuehai Liang & Yanfeng Wang, uniting decades of expertise in #RNAScience & #DrugDevelopment. Their vision drives our mission to deliver next-gen #AntisenseTherapeutics for patients with serious diseases.

🧬 https://www.arnatar.com/our-team

At Arnatar, we’re pioneering next-gen #RNAMedicines to treat severe & underserved diseases. Backed by our DARGER™ Platform, we advance antisense & #siRNA therapeutics that both up and down-regulate gene expression with precision.

Explore our pipeline: https://www.arnatar.com/pipeline

Arnatar announces publication of key patents for ACT-UP1, a first-in-class #antisense platform to #upregulate protein expression. A breakthrough for #haploinsufficient & #ProteinDeficiency diseases.

🧬 Learn more: https://bit.ly/41JBRDE

Arnatar Therapeutics has officially emerged from stealth.

With a $52M Series A led by Eight Roads & 3E Bioventures and ‪@fda.gov‬ #OrphanDrug + #RarePediatricDisease designations for ART4 in #AlagilleSyndrome, we’re advancing a new era of #RNABasedTherapies.‬

Learn more: https://bit.ly/4m39ec1

We're excited to announce a complete refresh of our corporate identity, along with a newly renovated website. This bold transformation highlights our innovative approach and commitment to scientific excellence.

Website: ARNATAR.com

Here is the website link.

Science Spotlight: Our proprietary ACT-UP1 mechanism enhances protein translation without modifying genetic code, a breakthrough for treating haploinsufficiency diseases like ALGS and ADPKD
#RareDisease #ADPKD #ALGS #Biotech

From antisense discovery in 1978 to today's breakthrough approvals - we're proud to be part of the 50-year journey that brought us 13 approved oligonucleotide drugs. The next generation starts now.

#RNAHistory #Milestones #Innovation #RNAi

Introducing our revolutionary DARGER™ platform - the first dual-functional antisense RNA technology enabling both up- and down-regulation of gene expression

Two ways to tackle disease, one powerful platform

#RNATherapeutics #Innovation #Biotech #RNAi